Endotoxin removal: How far from the evidence? from EUPHAS to EUPHRATES

Contributions to Nephrology

Volumn 167, Issue , 2010, Pages 111-118

  Rachoin, Jean Sebastien ^a   Foster, Debra ^b   Dellinger, R Phillip ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b Spectral Diagnostics Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; OXYGEN; POLYMYXIN B; VASOCONSTRICTOR AGENT;

ADULT; APACHE; ARTICLE; BLOOD; COST OF ILLNESS; ECONOMICS; HEMOPERFUSION; HUMAN; INTENSIVE CARE UNIT; ISOLATION AND PURIFICATION; JAPAN; META ANALYSIS; METHODOLOGY; MORTALITY; RISK REDUCTION; SEPTIC SHOCK; STATISTICS; SURVIVAL RATE; UNITED STATES;

ADULT; APACHE; COST OF ILLNESS; ENDOTOXINS; HEMOPERFUSION; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; JAPAN; META-ANALYSIS AS TOPIC; OXYGEN; POLYMYXIN B; RISK REDUCTION BEHAVIOR; SHOCK, SEPTIC; SURVIVAL RATE; UNITED STATES; VASOCONSTRICTOR AGENTS;

EID: 77954614452     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000315925     Document Type: Article

References (24)

1. Martin GS, Mannino DM, Eaton S, Moss M: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-1554.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
3. Castellanos-Ortega A, Suberviola B, Garcia- Astudillo LA, et al: Impact of the surviving sepsis campaign protocols on hospital length of stay and mortality in septic shock patients: results of a 3-year follow-up quasi-experimental study. Crit Care Med 2010, E-pub ahead of print.
4. Cinel I, Dellinger RP: Advances in pathogenesis and management of sepsis. Curr Opin Infect Dis 2007;20:345-352.
5. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL: Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993;328:1457-1460.
6. Suffredini AF, Fromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287.
7. Marshall JC, Foster D, Vincent JL, et al: Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 2004;190:527-534.
8. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993;119:771-778.
9. Opal SM, Gluck T: Endotoxin as a drug target. Crit Care Med 2003;31(Suppl 1): S57-S64.
10. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 1991;99:169-175.
11. Clark JA, Coopersmith CM: Intestinal crosstalk: a new paradigm for understanding the gut as the 'motor' of critical illness. Shock 2007;28:384-393.
12. Kellum JA: A targeted extracorporeal therapy for endotoxemia: the time has come. Crit Care 2007;11:137.
13. Bhor VM, Thomas CJ, Surolia N, Surolia A: Polymyxin B: an ode to an old antidote for endotoxic shock. Mol Biosyst 2005;1: 213-222.
14. Danner RL, Joiner KA, Rubin M, et al: Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother 1989;33: 1428-1434.
15. Shoji H: Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003;7:108-114.
16. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994;167:412-417.
17. Cruz DN, Perazella MA, Bellomo R, et al: Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.
18. Nakamura T, Matsuda T, Suzuki Y, Shoji H, Koide H: Polymyxin B-immobilized fiber hemoperfusion in patients with sepsis. Dial Transplant 2003;32:602-607.
19. Nemoto H, Nakamoto H, Okada H, et al: Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 2001;19:361-368, discussion 368-369.
20. Vincent JL, Laterre PF, Cohen J, et al: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intraabdominal infection. Shock 2005;23:400-405.
21. Cruz DN, Antonelli M, Fumagalli R, et al: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301: 2445-2452.
22. Nakamura T, Ushiyama C, Suzuki Y, et al: Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillinresistant Staphylococcus aureus. J Hosp Infect 2003;53:58-63.
23. Nakamura T, Ushiyama C, Suzuki Y, et al: Hemoperfusion with polymyxin B-immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureusassociated glomerulonephritis. Nephron Clin Pract 2003;94:c33-c39.
24. Marshall JC: Sepsis: rethinking the approach to clinical research. J Leukoc Biol 2008;83: 471-482.